Replies to post #222370 on Biotech Values

[Titan V]

Random notes on RXII:
— They have done 3 reverse splits in the last 5 years and are on track for a fourth one.
— Have overpromised and under delivered multiple times. Once delayed data two years.
— Have had senior clinical lead “retire” before overhyped data (Pamela Pavco, before cosmeceuticals data which was billed as a cash cow).
— They’ve pivoted from dermal scarring treatment to immuno oncology in recent years. I wish them the best but I would be very very careful of the management and be ready for a few more reverse splits.